Search PubMed⌕ Search

Biomedical subjects

W Roth

Publications and source records attributed to W Roth.

At least 91 records · Page 5Linked to original sources

Isoelectric focusing--polynucleotide/polyacrylamide-gel electrophoresis. A technique to separate and characterize nuclease activities.

Individual native nuclease activities from human leucocytes are separated by using two-dimensional gel electrophoresis in an apparatus that allows the simultaneous running of 28 gels. Proteins are separated by isoelectric focusing in a disc gel, followed by electrophoresis into a slab gel containing DNA. Protein denaturants are avoided in the second dimension by the use of a running pH well above the optimal pH for DNAase (deoxyribonuclease) activity. Electrophoresed gels are incubated in appropriate buffers to activate nuclease activity. After staining for intact DNA, the positions of active enzymes, unobscured by the presence of other proteins, are revealed as colourless spots in a reddish-purple field. The technique is easy to use and is sensitive to 50pg of DNAase I. Versatility is provided by the use of either acidic or basic electrophoresis running buffers and by the use of specific gel incubation conditions to reveal different sets of enzyme activities. Two DNAases active at pH 7.4 in the presence of Mg2+ and Ca2+, and sixteen DNAases active at acidic pH and not requiring metals, are detected. Treatment of the human enzymes with specific glycosidases reveals that many of the human DNAases are glycoproteins containing negatively charged moieties and may be derived from modification of parent activities.

Deoxyribonucleases↗

Fully-automated assay by liquid chromatography for routine drug monitoring in body fluids--method development with biological samples.

A fully-automated liquid chromatograph based on alternated pre-column enrichment technique has been developed for routine drug monitoring of body fluids using a column switching technique. Advantages of the method include the facility of direct injection of the body fluid onto the chromatograph and the simultaneous detection of both polar and non-polar metabolites under isocratic or gradient elution conditions.

Journal Article↗

Rapid, sensitive and fully automated high-performance liquid chromatographic assay with fluorescence detection for sulmazole and metabolites.

Sulmazole (2-[(2-methoxy-4-methylsulfinyl)phenyl]-3H-imidazo [4,5-b] pyridine; AR-L 115 BS) and two metabolites (sulfide, sulfone) were quantified from directly injected body fluids (plasma, urine, bile) after high-performance liquid chromatographic separation. No internal standard is needed, which is particularly advantageous when fluorescence detection is established. After automated pre-column enrichment on Corasil C18 (37-50 microns), the parent compound and biotransformation products could be backflushed and chromatographed on ODS-Hypersil (5 microns) with a mixture of 0.075 mol/l phosphate buffer-acetonitrile (2:1), an elution rate of 2.0 ml/min and fluorimetric detection (lambda ex = 330 nm; lambda em = 370 nm). A hydroxylated metabolite of sulmazole which occurs preferentially in urine (and bile) can be quantified in the above-mentioned solvent system diluted 1:1 with water, but with different fluorescence characteristics (lambda ex = 345 nm; lambda em = 515 nm). The assay was linear in the range 8-1000 ng/ml. The lower limit of detection was about 8 ng/ml or 80 pg with coefficients of variation between 0.4 and 5.8% for sulmazole.

Animals↗

Nonlinear pharmacokinetics of the new positive inotropic agent sulmazole in the dog.

Sulmazole (I) 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[ 4,5-b]pyridine, a new positive inotropic agent, is based on a pyridoimidazole nucleus. Sulmazole pharmacokinetics were monitored in plasma and urine by a specific, sensitive reverse-phase fully automated HPLC system with fluorimetric detection. The hydroxylated metabolite, III, was also monitored in the urine, and unusual pharmacokinetics were observed. Sulmazole disappeared and metabolite II appeared in plasma by zero-order rates for most of their time courses in the 2-15-mg/kg range with a 75% conversion to II. Pure Michaelis-Menten pharmacokinetics were not applicable, and the vmax value increased with increasing dose. Pharmacokinetics of sulmazole and II at 0.7-mg/kg iv doses were characterized by a first-order two-compartment body model. Metabolite III at 0.7- and 2-mg/kg iv doses showed no dose-dependent pharmacokinetics. The unchanged drug and its major metabolite, II, were negligibly excreted renally (0.5-2%). Their renal clearance showed urine flow rate dependencies. The plasma protein bindings were: sulmazole, 40.8 +/- 1.0%; II, 54 +/- 2%; III, 43 +/- 1%, and they were concentration independent.

Animals↗

[A case of arthritis caused by a tick bite (Lyme arthritis)].

A typical case of arthritis in the knee joint of a 49-year-old man caused by tick bite is reported. Based on this case report the manifestations of arthritis after erythema chronicum migrans so far published in literature are described.

Arthritis, Infectious↗

Fully automated high-performance liquid chromatography. A new chromatograph for pharmacokinetic drug monitoring by direct injection of body fluids.

A new fully automated high-performance liquid chromatography is described which detects drugs from directly injected plasma (urine, saliva) without sample pretreatment. The apparatus consists of a programmable automatic sampling unit, which is connected via two alternating working pre-columns to an analytical column ("alternating pre-column sample enrichment"). The new device is able to operate with directly injected body fluids like an auto-analyzer and is especially useful for pharmacokinetic and clinical studies, where drug concentrations have to be determined from plasma, urine or saliva.

Body Fluids↗

[AR-L 115 BS, comparison of human metabolite pattern and biotransformation with other species].

Following oral administration of 14C labelled 2-[(2-methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS) to the rat, rabbit, dog, rhesus monkey, baboon and man the metabolic pattern in plasma and urine was compared and human urinary metabolites were isolated. None of the animal species investigated shows a metabolic pattern identical to that of man. The plasma of rat, dog and rabbit shows wide variation of metabolites with high amounts of two unpolar metabolites of AR-L 115 BS (sulfoxide), namely M0/2 identical with AR-L 114 BS (sulfone with regard to AR-L 115 BS) and M0/1 identical with AR-L 113 BS (sulfide). In comparison to man the urines of the animals show higher amounts of the sulfone (AR-L 114 BS) and the sulfide (AR-L 113 BS). A main pathway of the metabolism of the pyrido-imidazole of the AR-L 115 BS-type is the oxidative pyridine-ring cleavage leading to N-acetylated 5-aminoimidazoles. Further metabolites are characterised by a hydroxyl group in the 6-position of the pyrido-imidazole moiety. Besides the oxidation of tthe sulfoxide function to the sulfone we could also observe the thioether (sulfide) not only of the parent compound itself but also of some of the metabolites in the series of the AR-L 115 BS-biotransformation. The identification of the human urinary metabolites, was carried out by means of TLC, HPLC, UV-, MS- and NMR-spectroscopy.

Administration, Oral↗

[Human pharmacokinetics of AR-L 115 BS (author's transl)].

Following i.v. administration of 0.7 mg of 2-[(2-methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS)/kg (bolus) the terminal plasma elimination half-life (beta-phase) was in the range of 50 min. A fast absorption of the patent compound could be observed after oral administration of 50, 75, 10 and 150 mg AR-L 115 BS (solution). The AR-L 115 BS plasma level behaviour was characterised by a fast elimination of the parent compound.

Administration, Oral↗

Structural changes in the heart due to mechanical perfusion.

Acute myocardial damage such as epicardial, intramural and subendocardial haemorrhages and oedema are known to occur after mechanical perfusion. The results of animal experiments showed that local circulatory disturbances (hypoperfusion, hypoxia) due to mechanical damage of the blood (erythrocyte aggregation, denaturation) and or lasting hypoperfusion (microcirculatory hypoxia) are responsible for the acute lesions. In addition, the results offer a morphological explanation for the postperfusion heart failure.

Animals↗